Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

Vaccine

Volumn 28, Issue 14, 2010, Pages 2624-2635

  Mangen, Marie Josee J ^a,b   van Duynhoven, Yvonne T H P ^b   Vennema, Harry ^b   van Pelt, Wilfrid ^b   Havelaar, Arie H ^b,c   de Melker, Hester E ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cost effectiveness; National immunization program; Rotavirus vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MARKET; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS; SCHOOL CHILD; VACCINATION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NETHERLANDS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 77649181424     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.014     Document Type: Article

References (65)

1. Desselberger U., Wolleswinkel-van den Bosch J., Mrukowicz J., Rodrigo C., Giaquinto C., and Vesikari T. Rotavirus types in Europe and their significance for vaccination. Pediatr Infect Dis J 25 Suppl. 1 (2006) S30-S41
2. de Wit M.A., Koopmans M.P., Kortbeek L.M., Wannet W.J., Vinje J., van Leusden F., et al. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol 154 7 (2001) 666-674
3. van Pelt W, Friesema I, Doorduyn Y, de Jager C, van Duynhoven YTHP. Bilthoven: National Institute of Public Health and the Environment; 2008. Report No.: Internal report.
4. Vesikari T., Giaquinto C., and Huppertz H.I. Clinical trials of rotavirus vaccines in europe. Pediatr Infect Dis J 25 Suppl. 1 (2006) S42-S47
5. Glass R.I., and Parashar U.D. The promise of new rotavirus vaccines. N Engl J Med 354 1 (2006) 75-77
6. Zomer T.P., van Duynhoven Y.T., Mangen M.J., van der Maas N.A., Vennema H., Boot H., et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 26 29-30 (2008) 3757-3764
7. Jit M., Bilcke J., Mangen M.J., Saldo H., Melliez H., Edmunds W.J., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 27 44 (2009) 6121-6128
8. Goossens L.M.A., Standaert B., Hartwig N., Hovels A.M., and Al M.J. The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands. Vaccine 26 (2008) 1118-1127
9. Goossens L.M.A., Standaert B., Hartwig N., Hovels A.M., and Al M.J. Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine 27 (2009) 2531-2532
10. de Wit M.A., Koopmans M.P., Kortbeek L.M., van Leeuwen N.J., Bartelds A.I., and van Duynhoven Y.T. Gastroenteritis in sentinel general practices, The Netherlands. Emerg Infect Dis 7 1 (2001) 82-91
11. Havelaar A.H., van Duynhoven Y.T.H.P., Nauta M.J., Bouwknegt M., Heuvelink A.E., de Wit G.A., et al. Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157 (2003), National Institute for Public Health and the Environment, Bilthoven Report No.: 284550008/2003
12. Havelaar A.H., van Duynhoven YTHP, Nauta M.J., Bouwknegt M., Heuvelink A.E., de Wit G.A., et al. Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157. Epidemiol Infect 132 3 (2004) 467-484
13. Fischer T.K., Nielsen N.M., Wohlfahrt J., and Paerregaard A. Incidence and cost of rotavirus hospitalizations in Denmark. Emerg Infect Dis 13 6 (2007) 855-859
14. Forster J., Guarino A., Parez N., Moraga F., Roman E., Mory O., et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European Children younger than 5 years of age. Pediatrics 123 3 (2009) 393-400
15. Harris J.P., Jit M., Cooper D., and Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 25 20 (2007) 3962-3970
16. de Wit M.A., Koopmans M.P., van der Blij J.F., and van Duynhoven Y.T. Hospital admissions for rotavirus infection in the Netherlands. Clin Infect Dis 31 3 (2000) 698-704
17. Chang H.G., Glass R.I., Smith P.F., Cicirello H.G., Holman R.C., and Morse D.L. Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000. Pediatr Infect Dis J 22 9 (2003) 808-814
18. Berner R., Schumacher R.F., Hameister S., and Forster J. Occurrence and impact of community-acquired and nosocomial rotavirus infections-a hospital-based study over 10 y. Acta Paediatr Suppl 88 426 (1999) 48-52
19. Jit M., Pebody R., Chen M., Andrews N., and Edmunds W.J. Estimating the number of deaths with rotavirus as a cause in England and wales. Hum Vaccin 3 1 (2007) 23-26
20. Lopez-de-Andres A., Jimenez-Garcia R., Carrasco-Garrido P., Alvaro-Meca A., Galarza P.G., and de Miguel A.G. Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001-2005. BMC Public Health 8 (2008) 109
21. Murray C.J., and Acharya A.K. Understanding DALYs (disability-adjusted life years). J Health Econ 16 (1997) 703-730
22. Murray C.J., and Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349 (1997) 1436-1442
23. Havelaar A.H., de Wit M.A.S., van Koningsveld R., and van Kempen E. Health burden in the Netherlands due to infection with thermophilic Campylobacter spp. Epidemiol Infect 125 3 (2000) 505-522
24. Haagsma J.A., Havelaar A.H., Janssen B.M.F., and Bonsel G.J. Disability Adjusted Life Years and minimal disease: application of a preference-based relevance criterion to rank enteric pathogens. Popul Health Metrics 6 7 (2008)
25. Bilcke J., Van Damme P., and Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 29 1 (2009) 33-50
26. Oostenbrink J.B., Bouwmans C.A.M., Koopmanschap M.A., and Rutten F.F.H. Handleiding voor kostenonderzoek-Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg (2004), College voor zorgverzekeringen, Diemen
27. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., and van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 14 2 (1995) 171-189
28. Koopmanschap M.A., and van Ineveld B.M. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 34 9 (1992) 1005-1010
29. Kemmeren J.M., Mangen M.J.J., van Duynhoven Y.T.H.P., and Havelaar A.H. Priorization of foodborne pathogens (2006), National Institute for Public Health and the Environment, Bilthoven Report No.: 330080001
30. Brouwer W.B.F., and Rutten F.F.H. De hoogte van de disconteervoeten in economische evaluaties: Is de tijd rijp voor een nieuwe richtlijn? (2005), Institute for Medical Technology Assessment, Rotterdam
31. Clark H.F., Offit P.A., Plotkin S.A., and Heaton P.M. The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr Infect Dis J 25 7 (2006) 577-583
32. Parashar U.D., Alexander J.P., and Glass R.I. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-12 (2006) 1-13
33. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis dung the first 2 years of life in European infants: randomised, double-bline controlled study. Lancet 370 (2007) 1757-1763
34. Newall A.T., Beutels P., Macartney K., Wood J., and MacIntyre C.R. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 25 52 (2007) 8851-8860
35. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 1 (2006) 11-22
36. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 1 (2006) 23-33
37. Phua K.B., Emmanuel S.C., Goh P., Quak S.H., Lee B.W., Han H.H., et al. A rotavirus vaccine for infants: the Asian experience. Ann Acad Med Singapore 35 1 (2006) 38-47
38. de Melker H.E., Hahne S., and de Boer I.M. The national immunisation programme in the Netherlands: current status and potential future developments (2004), National Institute for Public Health and the Environment, Bilthoven
39. de Wit M.A., Koopmans M.P., and van Duynhoven Y.T. Risk factors for norovirus, Sapporo-like virus, and group A rotavirus gastroenteritis. Emerg Infect Dis 9 12 (2003) 1563-1570
40. Mangen M.J.J., de Wit G.A., and Havelaar A.H. Economic analysis of campylobacter control in the Dutch broiler meat chain. Agribusiness 23 2 (2007) 173-192
41. Mangen M.J.J., Havelaar A.H., Poppe K.P., Wit G.A.D., and Team C.P. Cost-utility analysis to control Campylobacter on chicken meat-dealing with data limitations. Risk Analysis 27 4 (2007) 815-830
42. Mangen M.J.J., Havelaar A.H., and De Wit G.A. Campylobacteriosis and sequelae in the Netherlands-estimating the disease burden and the cost-of-illness (2004), National Institute of Public Health and the Environment, Bilthoven Report No.: 250911004
43. Mangen M.J.J., Havelaar A.H., Bernsen R.A.J.A.M., van Koningsveld R., and de Wit G.A. The costs of human Campylobacter infections and sequelae in the Netherlands: A DALY and cost-of-illness approach. Acta Agric Scand C: Food Econ 2 1 (2005) 35-51
44. Medley G.F., and Nokes D.J. Epidemiology. Does viral diversity matter?. Science 325 5938 (2009) 274-275
45. Vose D. Risk analysis: a quantitative guide (2000), John Wiley & Sons, Ltd., Chichester
46. De Wit G.A., and Schuit J. Overwegingen rondom de implementatie van kosten-effectieve public health interventies. Tijdschrift voor gezondheidswetenschappen 84 5 (2006) 11-13
47. Tate J.E., Panozzo C.A., Payne D.C., Patel M.M., Cortese M.M., Fowlkes A.L., et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 124 2 (2009) 465-471
48. Pitzer V.E., Viboud C., Simonsen L., Steiner C., Panozzo C.A., Alonso W.J., et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 325 5938 (2009) 290-294
49. van Duynhoven Y.T., de Jager C.M., Kortbeek L.M., Vennema H., Koopmans M.P., van Leusden F., et al. A one-year intensified study of outbreaks of gastroenteritis in The Netherlands. Epidemiol Infect 133 1 (2005) 9-21
50. Anonymous. Toename van rotavirusinfecties in instellingen. Infect Bull 17 7 (2006) 235
51. Bilcke J., and Beutels P. Reviewing the cost effectiveness of rotavirus vaccination the importance of uncertainty in the choice of data sources. Pharmacoeconomics 27 4 (2009) 281-297
52. de Wit M.A., Kortbeek L.M., Koopmans M.P., de Jager C.J., Wannet W.J., Bartelds A.I., et al. A comparison of gastroenteritis in a general practice-based study and a community-based study. Epidemiol Infect 127 3 (2001) 389-397
53. Jit M., and Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 25 20 (2007) 3971-3979
54. Lorgelly P.K., Joshi D., Iturriza Gomara M., Gray J., and Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 136 1 (2008) 44-55
55. Melliez H., Levybruhl D., Boelle P.Y., Dervaux B., Baron S., and Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 26 5 (2008) 706-715
56. Donker G. Continue morbiditeits registratie peilstations Nederland 2007 (2008), NIVEL, Utrecht
57. Food Standards A. A report of the study of infectious intestinal disease in England (2000), HMSO, London
58. Havelaar A.H., de Wit M.A.S., and van Koningsveld R. Health burden in the Netherlands (1990-1995) due to infection with thermophilic Campylobacter species (2000), Rijksinstituut voor volksgezondheid en milieu, Bilthoven, The Netherlands Report no. 284550 004
59. van den Brandhof W.E., De Wit G.A., de Wit M.A., and van Duynhoven Y.T. Costs of gastroenteritis in The Netherlands. Epidemiol Infect 132 2 (2004) 211-221
60. Hoogendoorn E.J.I., Feenstra T.L., and Rutten-van Molken M.P.M.H. Inventarisatie van het gebruik en de kosten van zorg voor astma en COPD in Nederland (2004), Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven
61. Ctg. Tariefboek medische specialisten - per 1 januari 2003. Utrecht: College Tarieven Gezondheidszorg (CTG); 2003.
62. Welte R, Jager JC, van Duynhoven YTHP, de Wit MAS. Economic evaluation of rotavirus vaccination in the Netherlands. Poster presented at the 39th annual meeting of the Infectious Diseases Society of America (IDSA), San Francisco, USA; 2001.
63. Le Roux P., Marshall B., Toutain F., Mary J.F., Pinon G., Briquet E., et al. Nosocomial viral infections in a pediatric service: example of rotaviral gastroenteritis and respiratory syncytial viral bronchiolitis. Arch Pediatr 11 8 (2004) 908-915
64. Roberts J.A., Cumberland P., Sockett P.N., Wheeler J., Rodrigues L.C., Sethi D., et al. The study of infectious intestinal disease in england: socio-economic impact. Epidemiol. Infect. 130 1 (2003) 1-11
65. Ctg. Entadministraties beleidsregels 2006 - circulaire CARE/201/05/3c - bijlage 3. College Tarieven Gezondheidszorg (CTG); 2005.